APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Urological Cancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Urological Cancer Drugs Market Analysis and Forecast 2026-2032

Report ID 174044660220 December 2025205 pages

Choose your research edition.

Industry ResearchUrological Cancer Drugs Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Urological Cancer Drugs Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Urological Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Urological Cancer Drugs Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Urological Cancer Drugs Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Urological Cancer Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Urological Cancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Urological Cancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Urological Cancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Urological Cancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Urological Cancer Drugs include Johnson & Johnson, Novartis, Pfizer, GlaxoSmithKline, AstraZeneca, Tolmar Inc, Sanofi S.A, Roche Healthcare and Ipsen, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Urological Cancer Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Urological Cancer Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Urological Cancer Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Urological Cancer Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Urological Cancer Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Urological Cancer Drugs sales, projected growth trends, production technology, application and end-user industry.

Urological Cancer Drugs Segment by Company

Johnson & Johnson

Novartis

Pfizer

GlaxoSmithKline

AstraZeneca

Tolmar Inc

Sanofi S.A

Roche Healthcare

Ipsen

Indevus Pharmaceuticals Inc

Ferring Pharmaceuticals

Dendreon Corporation

Celgene Corporation

Bristol-Myers Squibb

Astellas

Abbott Laboratories

Urological Cancer Drugs Segment by Type

Tablets

Injection

Urological Cancer Drugs Segment by Application

Bladder Cancer

Testicular Cancer

Prostate Cancer

Kidney Cancer

Others

Urological Cancer Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urological Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Urological Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urological Cancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Urological Cancer Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Urological Cancer Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Urological Cancer Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Urological Cancer Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Tablets Major Manufacturers Table 3. Injection Major Manufacturers Table 4. Global Urological Cancer Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Bladder Cancer Major Manufacturers Table 6. Testicular Cancer Major Manufacturers Table 7. Prostate Cancer Major Manufacturers Table 8. Kidney Cancer Major Manufacturers Table 9. Others Major Manufacturers Table 10. Urological Cancer Drugs Industry Trends Table 11. Urological Cancer Drugs Industry Drivers Table 12. Urological Cancer Drugs Industry Opportunities and Challenges Table 13. Urological Cancer Drugs Industry Restraints Table 14. Global Urological Cancer Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Urological Cancer Drugs Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Urological Cancer Drugs Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Urological Cancer Drugs Revenue Market Share by Region (2021-2026) Table 18. Global Urological Cancer Drugs Revenue Market Share by Region (2027-2032) Table 19. Global Urological Cancer Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global Urological Cancer Drugs Sales by Region (2021-2026) & (K Units) Table 21. Global Urological Cancer Drugs Sales by Region (2027-2032) & (K Units) Table 22. Global Urological Cancer Drugs Sales Market Share by Region (2021-2026) Table 23. Global Urological Cancer Drugs Sales Market Share by Region (2027-2032) Table 24. Global Urological Cancer Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Urological Cancer Drugs Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Urological Cancer Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Urological Cancer Drugs Sales Market Share by Manufacturers (2021-2026) Table 28. Global Urological Cancer Drugs Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Urological Cancer Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Urological Cancer Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Urological Cancer Drugs Manufacturers, Product Type & Application Table 32. Global Urological Cancer Drugs Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Urological Cancer Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Urological Cancer Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Urological Cancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Urological Cancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Urological Cancer Drugs Revenue Market Share by Type (2021-2026) Table 39. Global Urological Cancer Drugs Revenue Market Share by Type (2027-2032) Table 40. Global Urological Cancer Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global Urological Cancer Drugs Sales by Type (2021-2026) & (K Units) Table 42. Global Urological Cancer Drugs Sales by Type (2027-2032) & (K Units) Table 43. Global Urological Cancer Drugs Sales Market Share by Type (2021-2026) Table 44. Global Urological Cancer Drugs Sales Market Share by Type (2027-2032) Table 45. Global Urological Cancer Drugs Price by Type (2021-2026) & (US$/Unit) Table 46. Global Urological Cancer Drugs Price by Type (2027-2032) & (US$/Unit) Table 47. Global Urological Cancer Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Urological Cancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Urological Cancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Urological Cancer Drugs Revenue Market Share by Application (2021-2026) Table 51. Global Urological Cancer Drugs Revenue Market Share by Application (2027-2032) Table 52. Global Urological Cancer Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global Urological Cancer Drugs Sales by Application (2021-2026) & (K Units) Table 54. Global Urological Cancer Drugs Sales by Application (2027-2032) & (K Units) Table 55. Global Urological Cancer Drugs Sales Market Share by Application (2021-2026) Table 56. Global Urological Cancer Drugs Sales Market Share by Application (2027-2032) Table 57. Global Urological Cancer Drugs Price by Application (2021-2026) & (US$/Unit) Table 58. Global Urological Cancer Drugs Price by Application (2027-2032) & (US$/Unit) Table 59. Johnson & Johnson Company Information Table 60. Johnson & Johnson Business Overview Table 61. Johnson & Johnson Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Johnson & Johnson Urological Cancer Drugs Product Portfolio Table 63. Johnson & Johnson Recent Development Table 64. Novartis Company Information Table 65. Novartis Business Overview Table 66. Novartis Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Novartis Urological Cancer Drugs Product Portfolio Table 68. Novartis Recent Development Table 69. Pfizer Company Information Table 70. Pfizer Business Overview Table 71. Pfizer Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Pfizer Urological Cancer Drugs Product Portfolio Table 73. Pfizer Recent Development Table 74. GlaxoSmithKline Company Information Table 75. GlaxoSmithKline Business Overview Table 76. GlaxoSmithKline Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. GlaxoSmithKline Urological Cancer Drugs Product Portfolio Table 78. GlaxoSmithKline Recent Development Table 79. AstraZeneca Company Information Table 80. AstraZeneca Business Overview Table 81. AstraZeneca Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. AstraZeneca Urological Cancer Drugs Product Portfolio Table 83. AstraZeneca Recent Development Table 84. Tolmar Inc Company Information Table 85. Tolmar Inc Business Overview Table 86. Tolmar Inc Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Tolmar Inc Urological Cancer Drugs Product Portfolio Table 88. Tolmar Inc Recent Development Table 89. Sanofi S.A Company Information Table 90. Sanofi S.A Business Overview Table 91. Sanofi S.A Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Sanofi S.A Urological Cancer Drugs Product Portfolio Table 93. Sanofi S.A Recent Development Table 94. Roche Healthcare Company Information Table 95. Roche Healthcare Business Overview Table 96. Roche Healthcare Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Roche Healthcare Urological Cancer Drugs Product Portfolio Table 98. Roche Healthcare Recent Development Table 99. Ipsen Company Information Table 100. Ipsen Business Overview Table 101. Ipsen Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Ipsen Urological Cancer Drugs Product Portfolio Table 103. Ipsen Recent Development Table 104. Indevus Pharmaceuticals Inc Company Information Table 105. Indevus Pharmaceuticals Inc Business Overview Table 106. Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Indevus Pharmaceuticals Inc Urological Cancer Drugs Product Portfolio Table 108. Indevus Pharmaceuticals Inc Recent Development Table 109. Ferring Pharmaceuticals Company Information Table 110. Ferring Pharmaceuticals Business Overview Table 111. Ferring Pharmaceuticals Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Ferring Pharmaceuticals Urological Cancer Drugs Product Portfolio Table 113. Ferring Pharmaceuticals Recent Development Table 114. Dendreon Corporation Company Information Table 115. Dendreon Corporation Business Overview Table 116. Dendreon Corporation Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Dendreon Corporation Urological Cancer Drugs Product Portfolio Table 118. Dendreon Corporation Recent Development Table 119. Celgene Corporation Company Information Table 120. Celgene Corporation Business Overview Table 121. Celgene Corporation Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Celgene Corporation Urological Cancer Drugs Product Portfolio Table 123. Celgene Corporation Recent Development Table 124. Bristol-Myers Squibb Company Information Table 125. Bristol-Myers Squibb Business Overview Table 126. Bristol-Myers Squibb Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Bristol-Myers Squibb Urological Cancer Drugs Product Portfolio Table 128. Bristol-Myers Squibb Recent Development Table 129. Astellas Company Information Table 130. Astellas Business Overview Table 131. Astellas Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Astellas Urological Cancer Drugs Product Portfolio Table 133. Astellas Recent Development Table 134. Abbott Laboratories Company Information Table 135. Abbott Laboratories Business Overview Table 136. Abbott Laboratories Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Abbott Laboratories Urological Cancer Drugs Product Portfolio Table 138. Abbott Laboratories Recent Development Table 139. North America Urological Cancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 140. North America Urological Cancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 141. North America Urological Cancer Drugs Sales by Type (2021-2026) & (K Units) Table 142. North America Urological Cancer Drugs Sales by Type (2027-2032) & (K Units) Table 143. North America Urological Cancer Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 144. North America Urological Cancer Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 145. North America Urological Cancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 146. North America Urological Cancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 147. North America Urological Cancer Drugs Sales by Application (2021-2026) & (K Units) Table 148. North America Urological Cancer Drugs Sales by Application (2027-2032) & (K Units) Table 149. North America Urological Cancer Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 150. North America Urological Cancer Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 151. North America Urological Cancer Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 152. North America Urological Cancer Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 153. North America Urological Cancer Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 154. North America Urological Cancer Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 155. North America Urological Cancer Drugs Sales by Country (2021-2026) & (K Units) Table 156. North America Urological Cancer Drugs Sales by Country (2027-2032) & (K Units) Table 157. North America Urological Cancer Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 158. North America Urological Cancer Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 159. United States Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 160. Canada Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 161. Europe Urological Cancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 162. Europe Urological Cancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 163. Europe Urological Cancer Drugs Sales by Type (2021-2026) & (K Units) Table 164. Europe Urological Cancer Drugs Sales by Type (2027-2032) & (K Units) Table 165. Europe Urological Cancer Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 166. Europe Urological Cancer Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 167. Europe Urological Cancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 168. Europe Urological Cancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 169. Europe Urological Cancer Drugs Sales by Application (2021-2026) & (K Units) Table 170. Europe Urological Cancer Drugs Sales by Application (2027-2032) & (K Units) Table 171. Europe Urological Cancer Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 172. Europe Urological Cancer Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 173. Europe Urological Cancer Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 174. Europe Urological Cancer Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 175. Europe Urological Cancer Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 176. Europe Urological Cancer Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 177. Europe Urological Cancer Drugs Sales by Country (2021-2026) & (K Units) Table 178. Europe Urological Cancer Drugs Sales by Country (2027-2032) & (K Units) Table 179. Europe Urological Cancer Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 180. Europe Urological Cancer Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 181. Germany Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 182. France Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 183. U.K. Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 184. Italy Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 185. Netherlands Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 186. Nordic Countries Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 187. China Urological Cancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 188. China Urological Cancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 189. China Urological Cancer Drugs Sales by Type (2021-2026) & (K Units) Table 190. China Urological Cancer Drugs Sales by Type (2027-2032) & (K Units) Table 191. China Urological Cancer Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 192. China Urological Cancer Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 193. China Urological Cancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 194. China Urological Cancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 195. China Urological Cancer Drugs Sales by Application (2021-2026) & (K Units) Table 196. China Urological Cancer Drugs Sales by Application (2027-2032) & (K Units) Table 197. China Urological Cancer Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 198. China Urological Cancer Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 199. Asia Urological Cancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 200. Asia Urological Cancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 201. Asia Urological Cancer Drugs Sales by Type (2021-2026) & (K Units) Table 202. Asia Urological Cancer Drugs Sales by Type (2027-2032) & (K Units) Table 203. Asia Urological Cancer Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 204. Asia Urological Cancer Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 205. Asia Urological Cancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 206. Asia Urological Cancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 207. Asia Urological Cancer Drugs Sales by Application (2021-2026) & (K Units) Table 208. Asia Urological Cancer Drugs Sales by Application (2027-2032) & (K Units) Table 209. Asia Urological Cancer Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 210. Asia Urological Cancer Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 211. Asia Urological Cancer Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 212. Asia Urological Cancer Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 213. Asia Urological Cancer Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 214. Asia Urological Cancer Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 215. Asia Urological Cancer Drugs Sales by Country (2021-2026) & (K Units) Table 216. Asia Urological Cancer Drugs Sales by Country (2027-2032) & (K Units) Table 217. Asia Urological Cancer Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 218. Asia Urological Cancer Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 219. Japan Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 220. South Korea Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 221. India Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 222. Australia Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 223. China Taiwan Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 224. Southeast Asia Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 225. SAMEA Urological Cancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 226. SAMEA Urological Cancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 227. SAMEA Urological Cancer Drugs Sales by Type (2021-2026) & (K Units) Table 228. SAMEA Urological Cancer Drugs Sales by Type (2027-2032) & (K Units) Table 229. SAMEA Urological Cancer Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 230. SAMEA Urological Cancer Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 231. SAMEA Urological Cancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 232. SAMEA Urological Cancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 233. SAMEA Urological Cancer Drugs Sales by Application (2021-2026) & (K Units) Table 234. SAMEA Urological Cancer Drugs Sales by Application (2027-2032) & (K Units) Table 235. SAMEA Urological Cancer Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 236. SAMEA Urological Cancer Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 237. SAMEA Urological Cancer Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 238. SAMEA Urological Cancer Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 239. SAMEA Urological Cancer Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 240. SAMEA Urological Cancer Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 241. SAMEA Urological Cancer Drugs Sales by Country (2021-2026) & (K Units) Table 242. SAMEA Urological Cancer Drugs Sales by Country (2027-2032) & (K Units) Table 243. SAMEA Urological Cancer Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 244. SAMEA Urological Cancer Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 245. Brazil Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 246. Argentina Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 247. Chile Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 248. Colombia Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 249. Peru Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 250. Saudi Arabia Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 251. Israel Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 252. UAE Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 253. Turkey Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 254. Iran Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 255. Egypt Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 256. Key Raw Materials Table 257. Raw Materials Key Suppliers Table 258. Urological Cancer Drugs Distributors List Table 259. Urological Cancer Drugs Customers List Table 260. Research Programs/Design for This Report Table 261. Authors List of This Report Table 262. Secondary Sources Table 263. Primary Sources List of Figures Figure 1. Urological Cancer Drugs Image Figure 2. Global Urological Cancer Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Urological Cancer Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Tablets Image Figure 5. Injection Image Figure 6. Global Urological Cancer Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Urological Cancer Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Bladder Cancer Image Figure 9. Testicular Cancer Image Figure 10. Prostate Cancer Image Figure 11. Kidney Cancer Image Figure 12. Others Image Figure 13. Global Urological Cancer Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Figure 15. Global Urological Cancer Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Urological Cancer Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Urological Cancer Drugs Revenue Market Share by Region (2021-2032) Figure 18. Global Urological Cancer Drugs Sales (2021-2032) & (K Units) Figure 19. Global Urological Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global Urological Cancer Drugs Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Urological Cancer Drugs Sales YoY (2021-2032) & (K Units) Figure 22. Europe Urological Cancer Drugs Sales YoY (2021-2032) & (K Units) Figure 23. China Urological Cancer Drugs Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) Urological Cancer Drugs Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa Urological Cancer Drugs Sales YoY (2021-2032) & (K Units) Figure 26. Global Urological Cancer Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Urological Cancer Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Urological Cancer Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Urological Cancer Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Urological Cancer Drugs Revenue Market Share by Type (2021-2032) Figure 32. Global Urological Cancer Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global Urological Cancer Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Urological Cancer Drugs Sales Market Share by Type (2021-2032) Figure 35. Global Urological Cancer Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Urological Cancer Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Urological Cancer Drugs Revenue Market Share by Application (2021-2032) Figure 38. Global Urological Cancer Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global Urological Cancer Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Urological Cancer Drugs Sales Market Share by Application (2021-2032) Figure 41. North America Urological Cancer Drugs Revenue Share by Type (2021-2032) Figure 42. North America Urological Cancer Drugs Sales Share by Type (2021-2032) Figure 43. North America Urological Cancer Drugs Revenue Share by Application (2021-2032) Figure 44. North America Urological Cancer Drugs Sales Share by Application (2021-2032) Figure 45. North America Urological Cancer Drugs Revenue Share by Country (2021-2032) Figure 46. North America Urological Cancer Drugs Sales Share by Country (2021-2032) Figure 47. Europe Urological Cancer Drugs Revenue Share by Type (2021-2032) Figure 48. Europe Urological Cancer Drugs Sales Share by Type (2021-2032) Figure 49. Europe Urological Cancer Drugs Revenue Share by Application (2021-2032) Figure 50. Europe Urological Cancer Drugs Sales Share by Application (2021-2032) Figure 51. Europe Urological Cancer Drugs Revenue Share by Country (2021-2032) Figure 52. Europe Urological Cancer Drugs Sales Share by Country (2021-2032) Figure 53. China Urological Cancer Drugs Revenue Share by Type (2021-2032) Figure 54. China Urological Cancer Drugs Sales Share by Type (2021-2032) Figure 55. China Urological Cancer Drugs Revenue Share by Application (2021-2032) Figure 56. China Urological Cancer Drugs Sales Share by Application (2021-2032) Figure 57. Asia Urological Cancer Drugs Revenue Share by Type (2021-2032) Figure 58. Asia Urological Cancer Drugs Sales Share by Type (2021-2032) Figure 59. Asia Urological Cancer Drugs Revenue Share by Application (2021-2032) Figure 60. Asia Urological Cancer Drugs Sales Share by Application (2021-2032) Figure 61. Asia Urological Cancer Drugs Revenue Share by Country (2021-2032) Figure 62. Asia Urological Cancer Drugs Sales Share by Country (2021-2032) Figure 63. SAMEA Urological Cancer Drugs Revenue Share by Type (2021-2032) Figure 64. SAMEA Urological Cancer Drugs Sales Share by Type (2021-2032) Figure 65. SAMEA Urological Cancer Drugs Revenue Share by Application (2021-2032) Figure 66. SAMEA Urological Cancer Drugs Sales Share by Application (2021-2032) Figure 67. SAMEA Urological Cancer Drugs Revenue Share by Country (2021-2032) Figure 68. SAMEA Urological Cancer Drugs Sales Share by Country (2021-2032) Figure 69. Urological Cancer Drugs Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Urological Cancer Drugs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Tablets
  • Injection
Applications
  • Bladder Cancer
  • Testicular Cancer
  • Prostate Cancer
  • Kidney Cancer
  • Others
Companies covered
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Tolmar Inc
  • Sanofi S.A
  • Roche Healthcare
  • Ipsen
  • Indevus Pharmaceuticals Inc
  • Ferring Pharmaceuticals
  • Dendreon Corporation
  • Celgene Corporation
  • Bristol-Myers Squibb
  • Astellas
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Urological Cancer Drugs Market by Type
  3. 1.2.1 Global Urological Cancer Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Tablets
  5. 1.2.3 Injection
  6. 1.3 Urological Cancer Drugs Market by Application
  7. 1.3.1 Global Urological Cancer Drugs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Bladder Cancer
  9. 1.3.3 Testicular Cancer
  10. 1.3.4 Prostate Cancer
  11. 1.3.5 Kidney Cancer
  12. 1.3.6 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Urological Cancer Drugs Market Dynamics
  1. 2.1 Urological Cancer Drugs Industry Trends
  2. 2.2 Urological Cancer Drugs Industry Drivers
  3. 2.3 Urological Cancer Drugs Industry Opportunities and Challenges
  4. 2.4 Urological Cancer Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Urological Cancer Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Urological Cancer Drugs Revenue by Region
  3. 3.2.1 Global Urological Cancer Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Urological Cancer Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Urological Cancer Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Urological Cancer Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Urological Cancer Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Urological Cancer Drugs Sales by Region
  9. 3.4.1 Global Urological Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Urological Cancer Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Urological Cancer Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Urological Cancer Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Urological Cancer Drugs Revenue by Manufacturers
  2. 4.1.1 Global Urological Cancer Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Urological Cancer Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Urological Cancer Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Urological Cancer Drugs Sales by Manufacturers
  6. 4.2.1 Global Urological Cancer Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Urological Cancer Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Urological Cancer Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Urological Cancer Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Urological Cancer Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Urological Cancer Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Urological Cancer Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Urological Cancer Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Urological Cancer Drugs Market CR5 and HHI
  16. 4.8.2 2025 Urological Cancer Drugs Tier 1, Tier 2, and Tier 3
5 Urological Cancer Drugs Market by Type
  1. 5.1 Global Urological Cancer Drugs Revenue by Type
  2. 5.1.1 Global Urological Cancer Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Urological Cancer Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Urological Cancer Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Urological Cancer Drugs Sales by Type
  6. 5.2.1 Global Urological Cancer Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Urological Cancer Drugs Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Urological Cancer Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Urological Cancer Drugs Price by Type
6 Urological Cancer Drugs Market by Application
  1. 6.1 Global Urological Cancer Drugs Revenue by Application
  2. 6.1.1 Global Urological Cancer Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Urological Cancer Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Urological Cancer Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Urological Cancer Drugs Sales by Application
  6. 6.2.1 Global Urological Cancer Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Urological Cancer Drugs Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Urological Cancer Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Urological Cancer Drugs Price by Application
7 Company Profiles
  1. 7.1 Johnson & Johnson
  2. 7.1.1 Johnson & Johnson Company Information
  3. 7.1.2 Johnson & Johnson Business Overview
  4. 7.1.3 Johnson & Johnson Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Johnson & Johnson Urological Cancer Drugs Product Portfolio
  6. 7.1.5 Johnson & Johnson Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Novartis Urological Cancer Drugs Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Urological Cancer Drugs Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 GlaxoSmithKline
  20. 7.4.1 GlaxoSmithKline Company Information
  21. 7.4.2 GlaxoSmithKline Business Overview
  22. 7.4.3 GlaxoSmithKline Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 GlaxoSmithKline Urological Cancer Drugs Product Portfolio
  24. 7.4.5 GlaxoSmithKline Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca Urological Cancer Drugs Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 Tolmar Inc
  32. 7.6.1 Tolmar Inc Company Information
  33. 7.6.2 Tolmar Inc Business Overview
  34. 7.6.3 Tolmar Inc Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Tolmar Inc Urological Cancer Drugs Product Portfolio
  36. 7.6.5 Tolmar Inc Recent Developments
  37. 7.7 Sanofi S.A
  38. 7.7.1 Sanofi S.A Company Information
  39. 7.7.2 Sanofi S.A Business Overview
  40. 7.7.3 Sanofi S.A Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Sanofi S.A Urological Cancer Drugs Product Portfolio
  42. 7.7.5 Sanofi S.A Recent Developments
  43. 7.8 Roche Healthcare
  44. 7.8.1 Roche Healthcare Company Information
  45. 7.8.2 Roche Healthcare Business Overview
  46. 7.8.3 Roche Healthcare Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Roche Healthcare Urological Cancer Drugs Product Portfolio
  48. 7.8.5 Roche Healthcare Recent Developments
  49. 7.9 Ipsen
  50. 7.9.1 Ipsen Company Information
  51. 7.9.2 Ipsen Business Overview
  52. 7.9.3 Ipsen Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Ipsen Urological Cancer Drugs Product Portfolio
  54. 7.9.5 Ipsen Recent Developments
  55. 7.10 Indevus Pharmaceuticals Inc
  56. 7.10.1 Indevus Pharmaceuticals Inc Company Information
  57. 7.10.2 Indevus Pharmaceuticals Inc Business Overview
  58. 7.10.3 Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Indevus Pharmaceuticals Inc Urological Cancer Drugs Product Portfolio
  60. 7.10.5 Indevus Pharmaceuticals Inc Recent Developments
  61. 7.11 Ferring Pharmaceuticals
  62. 7.11.1 Ferring Pharmaceuticals Company Information
  63. 7.11.2 Ferring Pharmaceuticals Business Overview
  64. 7.11.3 Ferring Pharmaceuticals Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Ferring Pharmaceuticals Urological Cancer Drugs Product Portfolio
  66. 7.11.5 Ferring Pharmaceuticals Recent Developments
  67. 7.12 Dendreon Corporation
  68. 7.12.1 Dendreon Corporation Company Information
  69. 7.12.2 Dendreon Corporation Business Overview
  70. 7.12.3 Dendreon Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Dendreon Corporation Urological Cancer Drugs Product Portfolio
  72. 7.12.5 Dendreon Corporation Recent Developments
  73. 7.13 Celgene Corporation
  74. 7.13.1 Celgene Corporation Company Information
  75. 7.13.2 Celgene Corporation Business Overview
  76. 7.13.3 Celgene Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Celgene Corporation Urological Cancer Drugs Product Portfolio
  78. 7.13.5 Celgene Corporation Recent Developments
  79. 7.14 Bristol-Myers Squibb
  80. 7.14.1 Bristol-Myers Squibb Company Information
  81. 7.14.2 Bristol-Myers Squibb Business Overview
  82. 7.14.3 Bristol-Myers Squibb Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Bristol-Myers Squibb Urological Cancer Drugs Product Portfolio
  84. 7.14.5 Bristol-Myers Squibb Recent Developments
  85. 7.15 Astellas
  86. 7.15.1 Astellas Company Information
  87. 7.15.2 Astellas Business Overview
  88. 7.15.3 Astellas Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Astellas Urological Cancer Drugs Product Portfolio
  90. 7.15.5 Astellas Recent Developments
  91. 7.16 Abbott Laboratories
  92. 7.16.1 Abbott Laboratories Company Information
  93. 7.16.2 Abbott Laboratories Business Overview
  94. 7.16.3 Abbott Laboratories Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Abbott Laboratories Urological Cancer Drugs Product Portfolio
  96. 7.16.5 Abbott Laboratories Recent Developments
8 North America
  1. 8.1 North America Urological Cancer Drugs Market Size by Type
  2. 8.1.1 North America Urological Cancer Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Urological Cancer Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Urological Cancer Drugs Price by Type (2021-2032)
  5. 8.2 North America Urological Cancer Drugs Market Size by Application
  6. 8.2.1 North America Urological Cancer Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Urological Cancer Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Urological Cancer Drugs Price by Application (2021-2032)
  9. 8.3 North America Urological Cancer Drugs Market Size by Country
  10. 8.3.1 North America Urological Cancer Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Urological Cancer Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Urological Cancer Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Urological Cancer Drugs Market Size by Type
  2. 9.1.1 Europe Urological Cancer Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Urological Cancer Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Urological Cancer Drugs Price by Type (2021-2032)
  5. 9.2 Europe Urological Cancer Drugs Market Size by Application
  6. 9.2.1 Europe Urological Cancer Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Urological Cancer Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Urological Cancer Drugs Price by Application (2021-2032)
  9. 9.3 Europe Urological Cancer Drugs Market Size by Country
  10. 9.3.1 Europe Urological Cancer Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Urological Cancer Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Urological Cancer Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Urological Cancer Drugs Market Size by Type
  2. 10.1.1 China Urological Cancer Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Urological Cancer Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Urological Cancer Drugs Price by Type (2021-2032)
  5. 10.2 China Urological Cancer Drugs Market Size by Application
  6. 10.2.1 China Urological Cancer Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Urological Cancer Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Urological Cancer Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Urological Cancer Drugs Market Size by Type
  2. 11.1.1 Asia Urological Cancer Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Urological Cancer Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Urological Cancer Drugs Price by Type (2021-2032)
  5. 11.2 Asia Urological Cancer Drugs Market Size by Application
  6. 11.2.1 Asia Urological Cancer Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Urological Cancer Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Urological Cancer Drugs Price by Application (2021-2032)
  9. 11.3 Asia Urological Cancer Drugs Market Size by Country
  10. 11.3.1 Asia Urological Cancer Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Urological Cancer Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Urological Cancer Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Urological Cancer Drugs Market Size by Type
  2. 12.1.1 SAMEA Urological Cancer Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Urological Cancer Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Urological Cancer Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Urological Cancer Drugs Market Size by Application
  6. 12.2.1 SAMEA Urological Cancer Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Urological Cancer Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Urological Cancer Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Urological Cancer Drugs Market Size by Country
  10. 12.3.1 SAMEA Urological Cancer Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Urological Cancer Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Urological Cancer Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Urological Cancer Drugs Value Chain Analysis
  2. 13.1.1 Urological Cancer Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Urological Cancer Drugs Production Mode & Process
  6. 13.2 Urological Cancer Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Urological Cancer Drugs Distributors
  9. 13.2.3 Urological Cancer Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst